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Abstract
Theup-regulationoftranscobalamins[hithertopositedasindicatingacentralneedforcobalamin(Cbl)in
inflammation], whose expression, like inducible nitric oxide synthase (iNOS), is Sp1- and interferon-
dependent, together with increased intracellular formation of glutathionylcobalamin (GSCbl),
adenosylcobalamin (AdoCbl), methylcobalamin (MeCbl), may be essential for the timely promotion
and later selective inhibition of iNOS and concordant regulation of endothelial and neuronal NOS
(eNOS/nNOS.) Cbl may ensure controlled high output of nitric oxide (NO) and its safe deployment,
because: (1) Cbl is ultimately responsible for the synthesis or availability of the NOS substrates and
cofactors heme, arginine, BH4 flavin adenine dinucleotide/flavin mononucleotide (FAD/FMN) and
NADPH, via the far-reaching effects of the two Cbl coenzymes, methionine synthase (MS) and
methylmalonyl CoA mutase (MCoAM) in, or on, the folate, glutathione, tricarboxylic acid (TCA) and
urea cycles, oxidative phosphorylation, glycolysis and the pentose phosphate pathway. Deficiency of any
of the NOS substrates and cofactors results in ‘uncoupled’ NOS reactions, decreased NO production and
increasedorexcessiveO2
2,H 2O2,O N O O
2and other reactive oxygen species (ROS),reactive nitric oxide
species (RNIS) leading to pathology. (2) Cbl is also the overlooked ultimate determinant of positive
glutathione status, which favours the formation of more benign NO species, s-nitrosothiols, the
predominant form in which NO is safely deployed. Cbl status may consequently act as a ‘back-up disc’
that ensures the active status of antioxidant systems, as well as reversing and modulating the effects of
nitrosylationincellsignaltransduction.NewevidenceshowsthatGSCblcan significantly promote iNOS/
eNOS NO synthesis in the early stages of inflammation, thus lowering high levels of tumour necrosis
factor-a that normally result in pathology, while existing evidence shows that in extreme nitrosative and
oxidative stress, GSCbl can regenerate the activity of enzymes important for eventual resolution, such as
glucose 6 phosphate dehydrogenase, which ensures NADPH supply, lactate dehydrogenase, and more;
with human clinical case studies of OHCbl for cyanide poisoning, suggesting Cbl may regenerate
aconitase and cytochrome c oxidase in the TCA cycle and oxidative phosphorylation. Thus, Cbl may
simultaneously promote a strong inflammatory response and the means to resolve it.
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A Scarlet Pimpernel for the Resolution of Inflammation? [1] proposed that vitamin B12,
cobalamin (Cbl), in all its various forms, is central to the effectiveness of the immune
inflammatory response, and that its deficiency, chronic, functional or ‘compartmental’,
may largely contribute to the aetiology of systemic inflammatory response system (SIRS)/
sepsis/septic shock, as well as autoimmune disease, central nervous system (CNS) disease,
cancer, in particular haematological malignancy [2], and the progression of AIDS. The
hitherto unexplained elevation of Cbl carrier proteins, the transcobalamins (TC I, II and
III), their receptors, and TC unsaturated B12 binding capacity (UBBC) in trauma,
infections, chronic inflammatory conditions [3–9] and some cancers [2,9–13] was seen to
signal a central need for Cbl as a principal regulator of inflammation. The initial hypothesis
proposed that Cbl might exert a pivotal effect on inflammation via regulation of the redox
sensitive transcription factor, NFkB [14], which determines the expression of a diversity of
genes encoding mediators of the pro- and anti-inflammatory phases of the immune
response: cytokines, chemokines and inducible enzymes, principally, cyclooxygenase (Cox
II), inducible nitric oxide synthase (iNOS) [15] and heme-oxygenase (HO-1) [16].
Regulated expression of such genes by NFkB, a family of rel protein homo- and
heterodimers (RelA/p65, RelB, cRel, p50, p52), ultimately determines cell survival or
proliferation, tissue repair and apoptosis. Evidence for five interrelated mechanisms by
which Cbl might regulate NFkB was put forward: (1) hormone-like regulation of tumour
necrosis factor-a (TNFa), through scavenging of excess nitric oxide (NO) by Cbl, as well as
through the selective inhibition by Cbl, in tandem with gluthathione, of iNOS; (2) Cbl-
quenching of NO radicals (RNIS) and reactive oxygen species (ROS), enhanced by Cbl’s
glutathione (GSH) sparing/promotional effect; (3) Cbl promotion of acetylcholine
synthesis, central to the neuro-immune cholinergic anti-inflammatory pathway; (4) Cbl’s
promotion of cellular energy and respiration via the tricarboxylic acid (TCA) cycle and
oxidative phosphorylation; (5) a bacteriostatic role of the TCS released by neutrophil
secondary granules during phagocytosis, which also appears to modulate the inflammatory
response [1].
Recent in vitro explorations of some aspects of the original hypothesis have shown that, at
least in the pro-inflammatory phase, Cbl does not inhibit NFkB [17], and that indeed
certain Cbls have a slightly promotional, although not statistically significant, effect on
NFkB [17]. What direct/indirect effect Cbl may have on NFkB in the anti-inflammatory
resolution phase of the immune response remains to be explored in a temporal in vivo
model [18]. However, a totally novel in vivo finding of a strong promotional effect of Cbl,
particularly glutathionylcobalamin (GSCbl), on iNOS, with simultaneous supportive
promotion of endothelial NOS (eNOS), in the early stages of inflammation [17] (further
corroborated by an inversely related suppression of the glucocorticoid, annexin-1, and
lower, well-regulated levels of TNFa) [17], may be consistent with one of the original
hypotheses, that the ubiquity of Cbl and GSH is due to their mutual regulation of NO, in a
continuous scavenger–donor redox dance [1]. Because NO produced by iNOS can
ultimately inhibit iNOS [19,20] in the resolution of inflammation, as wella sN F kB at its
conclusion [21,22], a direct promotional effect of Cbl, particularly GSCbl, on iNOS
induction [17] would mean that Cbl does ultimately regulate NFkB, indirectly, via NO
regulation. If this is so, Cbl status could be the fulcrum on which the entire immune system
turns. The Return of the Scarlet Pimpernel will attempt to explore how Cbl might act as
both a timely selective promoter and a selective inhibitor of iNOS, as well as a key regulator
of all three NOS in general.
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Cbl, C63–65H88O14N14PCo, vitamin B12 [23,24], a red crystalline, water-soluble substance
(molecular weight 1357kDa), comprises various polycyclic compounds, with a central
cobalt atom set within a planar, tetrapyrrole (corrin) ring, that resembles that of the
porphyrin of heme, except that it is less symmetrical. The upper b axial cobalt ligand is
variable and can combine with H2O, OH, CN, GSH and other thiols, and with Me and
Ado to form the coenzymes, methylcobalamin (MeCbl) and 5
19-deoxy-5-adenosylcobala-
min (AdoCbl) [10]. The latter two have a unique, covalent carbon–cobalt bond that gives
Cbl its remarkable chemical and biological reactivity, and makes it one of the most potent
physiological compounds, with a daily requirement of only 1 mg. The lower a axial ligand
for the principal forms of the vitamin is a
5–6dimethylbenzimidazole, ‘false’, nucleotide base
(DMBI) (Figure1). Cbl is nature’s most complex non-polymer molecule and the most
complex of the vitamins and enzymatic cofactors known to date. It is synthesized by
bacteria both in the soil and in the lumen of ruminants. Humans must derive Cbl from their
diet, chiefly liver, kidneys, red meat, oysters, egg yolk and yeast extract. Absorption from
food is also complex, as it involves the binding of Cbl in food by the Cbl transport protein
TCI in saliva, gastric acid to separate Cbl from protein, and intrinsic factor in the ileum, as
well as the transport protein, TCII [25]. In the circulation there are, in fact, three transport
Figure 1. Structure of vitamin B12 and its derivatives.
Cobalamin in inflammation II 183proteins, TC I, II and III, with separate functions [26]. Cbl also assumes different forms,
the two principally known being MeCbl (75–90% of the body pool of circulating Cbl,
transported chiefly on TCI) and the coenzyme AdoCbl (10–25% of endogenous Cbl,
transported chiefly on TCII). TCIII appears to remove Cbl analogues or corrinoids, and
cyanocobalamin (CNCbl) from the tissues and circulation and take them to the liver for
excretion in bile, as corrinoids seem to interfere with the function of Cbl, whereas CNCbl,
found mostly in the lungs of smokers [11], is probably an excretory, detoxification product
and is functionally inert. Cbl, which enters the circulation as OHCbl/H2OCbl, is
transported by TCII, via the TCII endocytosis ion channel receptor (TCIIr), into all
tissues and cells, where, after TCII degradation in the lysosomes, it is converted to MeCbl
and AdoCbl, and largely retained for use intracellularly [27], although some is exported on
TCII and TCIII [28]. MeCbl acts in the cytosol, AdoCbl in the mitochondria. Synthesized
primarily by granulocytes, high concentrations of TCI are found in the reticuloendothelial
system, in neutrophils, and in the liver. TCI is largely confined to the circulation, perhaps
as a mobile store of Cbl (to complement the larger, long-term storage of Cbl as MeCbl and
AdoCbl in the liver and the pool of free Cbl in the kidneys). TCI does not have a specialist
receptor, unlike TCII. Instead it is taken into the cell via a multipurpose receptor, the
asialoglycoprotein receptor, a liver-specific protein [29]. TCII, a low molecular weight
glycoprotein (43kDa), with b globulin mobility, delivers MeCbl, AdoCbl and OHCbl/
H2OCbl and other Cbls to the tissues. However, there is clearly some form of
communication and flexibility between the TCS: TCII carries the larger fraction of Cbl
present in portal vein blood than in hepatic and axillary vein blood. In disease, TCII
sometimes holds the bulk of Cbl present in peripheral blood [30], suggesting Cbl transfer
from TCI as needed. High concentrations of TCI are also found in extracellular fluids:
milk, saliva, tears, semen, amniotic and spinal fluid. Moreover, although every DNA
synthesizing cell in the body contains receptors for TCII, the principal TC in tissues, there
are nonetheless fine gradations of all three TCS present in cells, varying continuously in
amount and intracellular location, according to the cell type and stage of maturation [31].
The elegance and ubiquity of such a fine-tuned and flexible Cbl delivery system is further
adapted during inflammation with a rapid response in the liver and granulocytes to produce
marked elevations in the TCS, either I and/or II [3], their receptors [4] and UBBC [4,5].
This is true for both chronic inflammation [for example, rheumatoid arthritis (RA) [6],
systemic lupus erythematosus [7], diabetes, Crohn’s disease [8]] and acute inflammation,
including cancer-associated inflammation, trauma and infections [4,5]. The TCs and their
UBBC are also increased in Cbl deficiency [10], notably in the immune-compromised
(AIDS [23,32] and cancer patients [10–13,23,32]) and the elderly [33] (who have a
median of 40.5% Cbl deficiency) [34], the same two groups who are also most susceptible
and likely to succumb to SIRS/sepsis/severe sepsis and septic shock [35]. Although TCS
have been labelled ‘acute phase response proteins’, the possible significance of this has been
either overlooked and no crisis function ascribed to them, or, as in the case of TC elevations
in cancer, they have been negatively interpreted.
The mysterious go-between: GSCbl and B12 coenzymes
The conversion of aquacobalamin (H2OCbl) on cell entry to the coenzymes MeCbl and
AdoCbl is not straightforward. It apparently proceeds via the formation of the unusually
stable intermediate [36,37] GSCbl, the product of H2OCbl+ and excess reduced GSH only
[38–40].GSCbl is believed to be a major form of intracellular Cbl [41], although this has not
184 C. Wheatleyyet been proven unequivocally, and GSCbl’s exact biological role, other than as a principal
intermediate on the pathway to MeCbl and AdoCbl coenzyme formation [42], remains to be
fully explored. As befits its role as intermediate for MeCbl and AdoCbl formation, GSCbl
may be a true go-between and also act independently, both in the cytosol and mitochondria.
(The possible significance of such GSCbl flexibility will be discussed in the Hypothesis
section on the GSH, Cbl, NO triad relationship.) Recent chemical discoveries about GSCbl
may point to its potential biochemical significance. The observed rate constant for the
formation of GSCbl increases with decreasing pH, reaching a limit value at pH,6.
Conversely, the equilibrium constant for the formation of GSCbl from H2OCbl+ and GSH
in the pH range 4.50–6 increases with increasing pH [38]. Intracellular pH is tightly
regulated. However, unlike extracellular pH, which is a constant 7.3–7.4, intracellular pH
varies according to location and vocation, from 7–7.3 in the cytosol to 5–6 in the endosome,
with the pH also notably lowering in the lysosome, phagosome, and secretory granules to 5–6
or5.5[43]. Thus, I would proposethattheformation ofGSCbl is so setup that, as in degrees
of inflammation intracellular pH becomes even more acidic, GSCbl is formed increasingly
rapidly, but in controlled amounts, presumably to conserve its steady availability over the
crisis period. Then, as inflammation is resolved and cellular pH returns to normal, GSCbl
formation equilibrium increases and the rate constant decreases. Nevertheless, even at the
normal cytosolic pH of 7.4 and the normal body temperature of 37uC, conversion of
H2OCbl+ to GSCbl will occur almost instantaneously, with a half-life of 2.8sec for the
reaction with 5mM GSH [38]. (Levels of GSH in cells can range up to 10mM.)
ItmaybeanindexofthepreviouslypositedspecialrelationshipbetweenCbl andGSHthat
the much larger than expected formation constant for GSCbl shows that thiolate forms of
GSH are the first identifiable Cbl ligands to approach the remarkably high binding affinity of
CN to H2OCbl [38]. (Based on the pH dependence of KobsGSCbl in the pH region 4.5–6,
an estimate of K GSCbl in the order of 5610
9M
21 is the closest formation constant to that
of CN for H2OCbl<10
14M
21 [38].) It is pertinent also that AdoCbl formation is four times
greater from GSCbl than from H2OCbl or CNCbl [42]. In coenzyme formation, GSCbl is
postulated as interacting directly with the active sites of methionine synthase (MS) or
methylmalonyl CoA mutase (MCoAM), and after reduction to Cob(I)alamin it is believed it
may react respectively with s-adenosylmethionine (SAM) or adenosine triphosphate (ATP)
to form enzyme-bound MeCbl and AdoCbl [38]. It is not known whether some GSCbl is
protein bound intracellularly, or whether any of it is exported on TCII and TCIII, as small
amounts of MeCbl and AdoCbl are. However, both MeCbl and AdoCbl are largely protein
bound, and in an unexpected manner. A huge surprise for B12 chemists when the crystal
structures of the two enzyme-bound cofactors were elucidated, was that the DMBI, in both
enzyme-bound MeCbl and AdoCbl, is ‘base-off’, that is, the DMBIis no longer co-ordinated
to the cobalt, which is instead liganded or base-on to the imidazole Ne2 in one of the two
proteins’ histidine residues (histidine 759 and A610 for MS and MCoAM, respectively). The
DMBIhadbeen expected toplaya crucialallostericrole intheenzymes’catalysis,butinstead
is confined to functioning as an anchor sunk into a deep hydrophobic pocket in both enzymes
[1,44–46]. Some 16 Cbl-dependent enzyme reactions are known to date, of which only two,
possibly three, the latter is controversial [1,47,48], occur in man. Yet, these two Cbl-
dependent enzymes control key metabolic pathways, whose far-reaching relationships and
often ‘hidden hand’ (of the Scarlet Pimpernel) consequences ensure the protection of every
organ and system of the body.
As a methyl donor, MeCbl, via MS, reduces homocysteine to methionine, whicht h e n
combineswithATPtoformSAM,and ensuresgoodmethylationofDNA,RNA,protein, and
Cobalamin in inflammation II 185successful DNA replication [2,5,49]. (Therefore, Cbl, as well as folate, status should be
critical for cancer chemoprevention [2,5,49,50].) MS also reduces N
5-methyltetrahydrofolate
(NMTHF) to H4folate (THF), thus ensuring its bioavailability for purine and dTMP
synthesis [2,50]. AdoCbl, via MCoAM, mediates the isomerization of methylmalonyl-CoA to
the energy-rich thiol ester, succinyl CoA, the formation of which AdoCbl shares with a-
ketoglutarate (aKG). This means that Cbl acts at a critical stage in the Krebs or TCA cycle, as
succinyl CoA represents a metabolic branch point wherein intermediates may enter or exit the
cycle, leading ultimately to the release of guanosine triphosphate (GTP), a source of energy in
gluconeogenesis and protein synthesis, and, in collaboration with the electron transport
oxidative phosphorylation chain, to release of ATP. Succinyl CoA may also be converted to
succinate or condensed with glycine to form d-aminolevulate, the initial step in porphyrin
biosynthesis. The conversion of methylmalonyl-CoA to succinyl CoA is alsoi m p o r t a n tf o rt h e
catabolism of valine, isoleucine, methionine; the pyrimidine DNA-specific nucleobase,
thymine; odd-chain fatty acids; and degradation of the side-chain of cholesterol [51]. Cbl is
thus essential for cellular respiration and energy, and both protein synthesis and catabolism.
The web of complex inter-relationships sustained by the two mammalian Cbl coenzymes
is illustrated in Figure2. It may be seen from this that degrees of Cbl deficiency may result
in malfunction on many levels. Perhaps then, it is not surprising that, although some
remain sceptical, the Cbl chemical, biochemical, medical literature [52], including clinical
case histories, now supports claims, and increasing evidence, for the efficacy of Cbl in
everything from cancer [2,52], heart disease [52], autism [52], Alzheimer’s disease [52],
multiple sclerosis [52] and other neurological conditions [52], AIDS [52], SIRS/sepsis/
Figure 2. ‘What goes around comes around’: some central cobalamin relationships.
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[52], autoimmune disease [52], chronic fatigue syndrome [52], eczema and other skin
conditions [52], allergies [52], and, not least, growth and megaloblastic anaemia, as Cbl is
critical to haemopoiesis [52]. Patents granted or applied for include evidence that Cbl
promotes anti-inflammatory HO–1 while lowering inflammatory arachidonic acid
metabolites, such as 12(R)-HETE and 12(R)-DiHETE (USP 5,674,505): also that Cbl,
alone or combined with interferon or chemotherapeutic agents, is effective in viral,
proliferative and inflammatory disease, including hepatitis C and B, herpes, vesticular
stomatitis, autoimmune encephalomyelitis, multiple sclerosis and astrocyte gliomas (USP
application 2005/0163751 A1). This pleiotropic character of Cbl’s effects is curiously
reminiscent of that of NO. Is this just a coincidence?
The NOCbl controversy
The fact that Cbl has some kind of rapid physiological impact on NO, which might prove
beneficial in pathology involving unresolved inflammation, is suggested by various reports
dating back to 1991. Large intravenous doses of OHCbl significantly increased systemic
vascular resistance in normal conscious dogs [53]. The relaxation of isolated vascular and
visceral smooth muscle induced by NO and NO donors was reversed by OHCbl [54]. Mice
exposed to lipopolysaccharide (LPS) and given either CNCbl or OHCbl had a 30 and 40%
increased survival, respectively (with zero survival for the control group) [55]. OHCbl also
blocked NO-mediated inhibition of leukaemia cell proliferation [56]. Such data has led to the
popular view of Cbl’s role in inflammation as a scavenger for excess NO, supposedly
combining with it to form nitrosylcobalamin (NOCbl) [55–58]. Although studies show this
can happen, in a reversible manner, at the point of an electrode [59], the existence of NOCbl
has been much disputed by B12 chemists [56,60–62], and an alternative mechanism for
Cbl’s inactivation of NO has been proposed, as NOCbl is not thought to be a stable enough
complex to account for the inhibition/blockade of NO’s biological effects by Cbl. Based on
the observation that superoxide can, under certain conditions, lead to the rapid inactivation
of NO, it has been proposed that Cbl (III)O2
2, a superoxide species of Cbl that rapidly and
spontaneously regenerates in aerobic solutions, interacts with NO by forming ONOO
2
(peroxynitrite) in a cyclic mechanism for its rapid inactivation [60]. Although not
implausible, this mechanism remains hypothetical, as Cbl (III)O2
2 is too unstable and
difficult to purify for direct dose–response studies. A more recent study that apparently
established rapid interaction between NO and the Cbl of MS, in the Co
+1 state, Cbl (I),
basedonspectroscopicanalysis,proposedthatNO,atphysiologicallynormalconcentrations,
may regulate carbon flow through the folate pathway by inhibiting MS and decreasing rates
of methionine, serine, and de novo purine nucleotide synthesis. In this cell culture in vitro
model, homocysteine (Hcy)[63] was seen to act as an inhibitor of NO, a perhaps surprising
findinggiven that NO isnormally seen asanti-atherogenic,yetbyinactivatingMS,NO raised
the levels of supposedly pro-atherogenic homocysteine. This hints at a complexity in the NO/
Cbl relationship outside the study model’s parameters.
Moreover, much of the data cited above for direct NO/Cbl interaction is handicapped by
being largely based on purely chemical studies, or in vitro or isolated tissue studies that
necessarily omit full physiological complexity. The view that Cbl just scavenges NO has
always seemed too simplistic to the writer of this hypothesis. Combining with NO in a
physiologically consequential way is more the province of heme and non-heme iron, O2,
superoxide, GSH and other thiols [64]. If NOCbl has a physiological role, then maybe it is a
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proposed impact of NO on MS [63]. Nevertheless, it is still a question whether NOCbl exists
at all endogenously. So far NOCbl has not yet been detected in vivo (although it has been
given exogenously to mice as an effective anti-cancer agent [65]). Indeed, if Cbl were capable
ofcontinuouscompetitionwithhemeornon-hemeironorGSHasasuccessfulrivalforNO,it
might prove dangerous to life. Whereas, the rodent, large mammal and human clinical
literature demonstrates that Cbl in high, even extremely high, supra-physiological doses is a
life restorer in perilous situations, even capable of resurrecting the dead [66]. (‘Des souris en
e ´tat de mort appare `nte parairent e ˆtrere ´anime ´es par iv. 250mg/kg OHCbl, sans autre me ´sure’
after cyanide poisoning [66].) Apart from its traditional use as the treatment for subacute
neuronal degeneration of the spinal cord and pernicious anaemia, a discovery that in its day
was equivalent to finding a cure for cancer, Cbl has been shown to work safelyi nav a r i e t yo f
animal models: mice, rats [55], guinea-pigs [67], dogs [68], baboons [69] and in a variety of
extreme situations, from the trauma of radiation [70] and electrocution [71] to fatal injury
[68], anaphylactic [67] and septic shock [55]. In addition, Cbl has been used successfully for
over 40 years in the intensive care unit in France (but also latterly in Spain, Italy, Germany,
Hong Kong and China). The French case literature [72–76] documents near-miraculous
recoveries from cyanide poisoning with the use of OHCbl as an antidote, given in
extraordinarily high doses of 4–5g, sometimes repeated on consecutive days. At these doses,
the only side-effects reported were a transient urticaria or red rash. Cyanide victims thus
rescued are documented as recovering consciousness and cardiovascular function within
30min of Cbl infusion, and walking out of the intensive care unit within 2 days, with liver and
other vital organs intact. This is not the normal intensive care unit experience with such or
similar extreme conditions, and may not therefore, this hypothesis maintains, be solely
ascribed to the binding of cyanide by Cbl. The same supra-physiological 5g dose of OHCbl
given to normal heavy smoking volunteers produced only modest transient rises in blood
pressure and slight transient bradycardia [77], conditions that might be welcomed as side-
effects in sepsis or shock treatment. Indeed, if Cbl were just an NO mop, it might be expected
to cause dangerously high blood pressure and persistent vasoconstriction. Instead, few drugs
can hope to emulate Cbl’s proven pharmacological safety profile [53,72–77].
So the Cbl/NO relationship has to be more complex and interesting than the crude idea
of Cbl as just an NO mop. It is much more plausible, given the safety and efficacy literature,
that Cbl should exert a central control over NO, in part through the regulation of all three
NOS and through selective promotion and inhibition [1,78] of iNOS, as and where it is
needed. Because recent in vivo studies at the William Harvey Institute [17], with other
corroborative markers, show quite clearly that high-dose OHCbl, and particularly GSCbl,
promote iNOS mRNA in the early stages of LPS-induced inflammation, and because mice
given high-dose Cbl to treat LPS-induced sepsis show remarkable survival [55], it is
possible that Cbl first promotes iNOS NO production and later, in the resolution phase of
inflammation, inhibits it, perhaps over and above iNOS inhibition by NO itself. Moreover,
it may be that the high levels of iNOS NO production apparently promoted by Cbl,
particularly by GSCbl [17], in the pro-inflammatory phase are essential for regulating
inflammation and signalling entry into the resolution phase. The question is how?
Hypothesis
A well-regulated, successful immune inflammatory response is biphasic [79,80]. A pro-
inflammatory phase, entailing the tyrosine kinase phosphorylation cascade (MAPK) and
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which up-regulate the production of inflammatory cytokines, principally, TNFa,
interleukin 1b, interleukin-6, interferons a, b and c, chemokines, adhesion molecules,
growth factors, proteases, inducible enzymes such as HO-1, Cox II, iNOS, phospholipase
A2 as well as prostaglandins, particularly PGE-2, and other lipid mediators, such as platelet
activating factor, leukotrienes, thromboxanes, and tissue factor, which activate the extrinsic
coagulation cascade. Such pro-inflammatory factors radically change the redox environ-
ment at the site of inflammation, particularly in the macrophages [81] and neutrophils [82],
so that it becomes more oxidant. Increased oxidative products, such as superoxide (O2
2),
singlet oxygen, hydroxyl radicals, NO and its species, interact to form other potentially
lethal species, such as H2O2 and ONOO
2. These free radicals collectively play vital roles in
the immune response, acting both as signalling/acute response activation agents and as
cytotoxic agents [82–86]. For maximum lethality to the invader and minimum damage to
the host they must be deployed in a focussed and balanced manner [79], which has a
natural time limit and often a distinct, spatially confined, or discrete intracellular location
[86]. Key antioxidant enzyme systems up-regulated by decreasing pH, ensure that balance,
focus, time and spatial limitation, signal specificity and efficacy are maintained [84–88].
Superoxide dismutase (SOD), for example, removes excess superoxide using different
catalytic transition metals, Cu, Zn, Mn, in differing cell environments — mitochondria,
cytosol, phospholipid membrane [89]. Catalase scavenges H2O2 [90]. GSH [91], a major
reductant and detoxifier, continuously recycled by selenium-dependent GSH peroxidase
(GPX), which also scavenges H2O2, is subsequently reduced again by GSH reductase [91],
while glutathione-S-transferase is also up-regulated by the transcription factor AP-1, which is
under direct control by NO [92]. HO-1 breaks down heme to biliverdin [16], which in turn
yields the antioxidant, bilirubin [93]. Heme peroxidases, such as myeloperoxidase, consume
H2O2 in phagocytes and Cox II [90]. Glucose 6 phosphate dehydrogenase (G6PDH)
produces a steady stream of the reducing equivalent NADPH, needed for key enzyme
catalysis [94]. Thus, by a complex interplay of phosphorylating/redox-sensitive signalling/
response systems, the inflammatory phase of the immune response is normally self-limiting.
But rather than giving way in a see-saw manner to the resolution phase, the evidence so far
suggests that the anti-inflammatory phase is engaged early on, but, initially, at a much lower
level, its activity increasing as the peak of inflammation is reached and then declines. This
may depend on early parallel activation of the cholinergic immune pathway [95], in tandem
with the sympathetic/adrenal neuro-endocrine pathway, involving the release of glucocorti-
coids, such as Annexin 1 [96], and the catecholamines dopamine, epinephrine/norepineph-
rine; also the deployment of ‘good’ eicosanoids, such as the v-3 fatty acid, eicosapentanoic
acid, known to suppress TNFa and interleukin-1 [97], and various oxidized derivatives of
eicosapentanoic acid, neuro-protectins [98], resolvins [99], lipoxins [100]. Eventually anti-
inflammatory cytokines interleukin-4, interleukin-10 [101], interleukin-13, and growth
factors, epidermal growth factor (EGF) and transforming growth factor b1 (TGFb1) [102]
are fully expressed, preceded by the inhibition of iNOS and a change in sense of pro-
inflammatory factors such as nuclear translocated NFkB, Cox II and interleukin-6, which
can paradoxically also signal repair and resolution in due course [103].
In pathologies of unresolvable inflammation, chronic or acute, such as multiple sclerosis,
RA, or sepsis, the redox balance is lost, either locally or systemically, with devastating
results in the latter case. In sepsis, endogenous antioxidant enzyme systems can be depleted
within hours, with a 46–83% loss of activity in SOD and GPX, just 12hours into sepsis,
and a 52% reduction in the somewhat more resistant liver catalase [104]. With little to keep
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(RNIS) fuels the pro-inflammatory phase as it works in a feed-forward, continuously
amplifying loop of widespread endothelial and epithelial damage; a build-up of fibrin
impeding circulation in the microvasculature: unresponsive hypotension; and increasing
O2
2 and ONOO
2 dramatically impairing cellular respiration and energy production,
through increasing inhibition of aconitase in the Krebs cycle and complexes I to IV in the
mitochondrial oxidative phosphorylation, electron transport chain [105], all lead, if
prolonged, to cell death and eventual multi-organ failure.
It is commonly thought that the chief cause of such scenarios is NO overproduction by
iNOS [106–108], a view based largely on numerous in vitro studies, often with exogenous
NO donors, (studies, which by definition, omit the effect of potential systemic iNOS/nNOS
modulation systems, such as the increase in circulating and tissue entry TCS,) or on
murine studies that do not discriminate between iNOS mRNA and the potential for
variability in its redox products [109], or that use even less specific evidence, such as serum/
urine nitrite/nitrate. Although there is not much large mammal or human data for it [106],
such evidence as there is for this view, seems largely based on plasma and/or urine
measurements of nitrite, and nitrate, in RA or septic shock patients, for example [106–
108], as direct NO and NOS assays in vivo are fraught with difficulty [110]. But this
evidence is equivocal, as nitrite and nitrate do not necessarily indicate simply formation of
NO, but can equally well be derivatives of RNIS, such as ONOO
2, or its protonated
species, HNO [111]. Indeed, a recent study of nitrite/nitrate excretion in the serum, urine,
saliva and tears of RA and healthy age-matched controls, both on a low nitrate/nitrite diet,
found no significant differences, or relationships [112]. Moreover, nitrite and nitrate are
also products of protein catabolism [113], which is dramatically increased in pathologies of
acute unresolved inflammation, such as burn injury and sepsis [114]. The fact that NOS/
iNOS inhibitors can attenuate the hypotension of sepsis is also non-specific evidence for
putative NO damage. It can equally well be argued that iNOS inhibitors also inhibit the
production of RNIS, which may be much more likely candidates as a cause of hypotension
than NO. iNOS inhibitors will also considerably reduce the production of TNFa and
interleukin-1, and this too may be material, as high dose administration ofT N F a is known
to produce lethal hypotension [115], which may have been automatically attributed to
assumed high NO. Moreover, there is evidence that levels of NO have a direct regulatory
correlation to levels of TNFa. In a murine model using Staphylococcus B, NO inhibitors
increased sustained release of TNFa (and interferon-c), which increased enterotoxin
toxicity of Staphylococcus B [116]. Anti-interferon-c monoclonal antibodies were more
effective at NO reduction than anti-TNFa monoclonal antibodies, but together they
produced total NO inhibition [116]. This suggests the existence of a regulatory loop by
which NO inhibits the production of TNFa/interferon-c, which induces its own synthesis
[81,117,118]. This TNFa/NO relationship has been observed elsewhere. TGFb-1, usually
expressed in the resolution of inflammation, is a potent suppressor of NO in vitro and in
vivo, and TGFb-1 transgenic mice exposed to LPS show blunted production of NO, but an
eight-fold higher production of TNFa, as opposed to wild controls, with consequent
increased mortality [119]. The recent studies at the William Harvey Institute also
demonstrate this high NO–lower TNFa relationship, as a result of high-dose Cbl
administration in mice exposed to LPS [17]. Because Cbl has also been shown to exert
direct hormonal-like regulation of TNFa [120], it is reasonable to conclude that such Cbl/
TNFa regulation is the result of Cbl/NO regulation. The pleiotropic transcription factor
Sp1, which directly promotes transcription of the TCII gene [27] (up-regulated in
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transcription via the Sp1 binding site of its promoter, in response to iNOS NO production
[121]. Sp1 is moreover involved in the regulation of anti-inflammatory TGFb [122], and
epidermal growth factor [123], the latter known to be directly Cbl status dependent [120].
Thus, Sp1, the TC-Cbl carrier promoter, is responsible for parallel activation of pro- and
anti-inflammatory factors, just as this hypothesis proposes Cbl may be. The emphasis,
however, is on Sp1/Cbl-NO regulation of TNFa, not suppression. There must be a necessary
right level of TNFa for a successful immune response, as anti-TNFa antibodies in the clinic
increase mortality [124]. Similarly too, although it may seem an old, discarded paradigm,
there may be a right level of NO, higher in relation to TNFa, for a successful immune
response outcome. Hence, even setting aside the detrimental impact of non-selective NOS
inhibitors on eNOS, this is an additional explanation for the negative outcome of iNOS
suppression in sepsis with increased mortality in the clinic [106], prefigured in animal
models. iNOS knockout mice treated with LPS showed no significant survival over the wild-
type [125]. Other iNOS –/– mice showed no defence against Gram-positive bacteria, and
equal mortality and vital organ damage as the wild-type [126]. Furthermore, macrophages
derived from these iNOS –\– mice failed to restrain the replication of Listeria monocytogenes
in vivo and lymphoma cells in vitro. Since iNOS is primed to be inhibited by NO feedback
[19–21], itshould ineffectbe inhibitedby putative NO overproductionin sepsis.Clearly, itis
not. So, NO overproduction seems less plausible as the source of trouble.
This hypothesis, then, proposes a contrary scenario: it is not NO per se that is the
problem in unresolved inflammation. Rather, the problem may be a malfunction of iNOS,
resulting from degrees of mild, subclinical or ‘functional’ Cbl deficiency, which might also
involve ‘compartmental’ Cbl deficiency, with the local inactivation of one of the two Cbl
coenzymes, MS in the CNS, for example [127], allied perhaps to other factors such as age,
immune compromise, poor general nutritional status, and/or iNOS, TNFa, interferon,
platelet activating factor, TC, gastric atrophy, or other, genetic polymorphisms. A
polymorphism, in the iNOS gene, for example, which promotes greater NO production,
has been shown to confer greater resistance to malaria [128]. Polymorphisms in the
NRAMP1 gene, an intracellular NO chaperone, may also impact significantly on immune
resistance [129]. [As an epidemiological aside, US statistics show a significant increase of
139% in sepsis diagnoses since the 1980s, with the increase especially notable in patients
over 65 years of age (162%) [106], the very group notable for a 40.5% median Cbl
deficiency [32]. What is also notable since the 1980s is the introduction and widespread,
often indiscriminate, use of proton-pump inhibitors and H2-blocker drugs, both of which
interfere seriously with acid-dependent Cbl absorption [130,131]. The effects of the latter
may be amplified by a decline in consumption of liver and kidneys, the post-war
generation’s staple, and, latterly, red meat and eggs, all key sources of Cbl.]
The numerous studies that show a detrimental effect of iNOS activation on pro-
inflammatory factors do not appear to have taken into consideration that when iNOS, the
least tightly ‘coupled’ NOS isoform, malfunctions it can catalyse reactions that are partially
or largely ‘uncoupled’ from the production of NO [109,132–136], but result instead in an
excess of superoxide, H2O2 OONO
2 and other RNIS [137]. Consequently, levels of NO
may not be high enough for correct signalling, cytocidal and resolution purposes. iNOS
may then get stuck, like a needle in a groove, chronically producing increasingly even less
NO, and increasingly more dysregulating O2
2, other ROS and RNIS. Such RNIS,
produced in relatively modest amounts under normal conditions, play a very specific role in
cell signal transduction and regulation of enzyme synthesis and degradation, by reversible
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increasingly excessive amounts, RNIS such as OONO
2 can also affect the other principal
cell signalling system, responsible for cell cycle control, tyrosine phosphorylation
[138,139]. Nitration of tyrosine residues located near phosphorylation sites is irreversible,
and impairs both the rate of phosphorylation and its reversibility [140], contributing further
to unresolved inflammation.
This hypothesis also proposes that, in the absence of deficiency, Cbl may be the ultimate
supplier of the substrates and cofactors necessary for efficient, more coupled, iNOS/nNOS
NO production, as opposed to excess O2
2, OONO
2 and RNIS, and that it may
consequently be the ultimate determinant of the NO/O2
2 balance thought to be critical in
achieving NO regulation of ONOO
2-mediated signal specificity and response [86,136].
Moreover, Cbl, as GSCbl, may itself act as an additional direct promoter of iNOS, while
simultaneously also acting as a ‘back-up disc’ to preserve or reactivate key antioxidant
systems and enzymes that protect the host from damage during the immune inflammatory
response. The resolution phase is ushered in by Cbl positively shifting the antioxidant
balance, and having ensured effective, high levels of NO for a contained time span, so that
NO eventually inhibits iNOS. A tantalizing clue to this proposed Cbl/NO relationship is to
be found in the extraordinary capacity of liver for regeneration. In ancient mythology,
Prometheus, the Titan who stole fire from Zeus for mankind, was punished by having a
vulture devour his liver daily. Nightly, however, Prometheus’s liver regenerated. This is
scarcely myth: after resection of up to two-thirds of human liver, complete regeneration can
occur within 2 weeks. During this period, iNOS is continuously active, as in foetal
gestation. Might this powerful, safe and miraculous deployment of high NO over a long
period of time have anything to do with the fact that the liver, with up to 5 years’ supply, is
the largest depository of Cbl in the body? Let us now consider the possible mechanisms.
NOS: ‘in sickness and in health, for better or for worse’?
NO is produced by a family of NOS [136,141,142], heme-based enzymes that have a
catalytic resemblance to cytochrome P450 and other heme-based oxygenases. NOS have
been divided into three main classes: two constitutive forms, involved in respiration, cell
signal transduction and neuro-transmission, respectively: membrane bound, particulate
eNOS (NOS III), with a lipid anchor, targeted to the caveolae, the least active of the three
isoforms, found primarily in smooth muscle and vascular endothelium; nNOS (NOS I), in
the CNS/neurons and neuromuscular junctions; and iNOS (NOS II), produced in
inflammatory immune responses by polymorphonuclear/granulocytes (PMN), primarily
macrophages [81], the latter two enzymes both active in the cytosol. This rather simple
picture has been complicated of late by the discovery of multiple isoforms and splice
variants of NOS, and their discrete localization within subcellular compartments [86,136] –
somewhat reminiscent of the varying forms of Cbl/TC distribution, localization and action.
An example given is that of cardiac and skeletal muscle that coexpresses three different
NOS isoforms in four different locations: a plasmalemal NOS, regulating force production
and blood flow, a mitochondrial NOS, controlling respiration at the level of cytochrome c
oxidase, a sarcoplasmic reticular NOS, involved in calcium homeostasis and other
constitutive/inducible cytosolic NOS whose exact function/location had yet to be defined
[143]. m, a, b, c tissue-specific isoforms of nNOS are also known [144]. Moreover, iNOS,
hitherto thought to be active only briefly during immune responses, or chronically and
aberrantly in pathologies of unresolved inflammation, has been shown to be continuously
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myocardium [146], retina [147], liver [148], bronchial epithelium [149], and also in
murine ileum [150]. Since continuously expressed iNOS in the latter locations clearly has a
positive protective function, removed from persistent pathology, (the lungs are
continuously exposed to pathogens and iNOS NO in bronchial epithelium [151], yet
most people do not have asthma, for example,) iNOS must be very tightly regulated, with
strong endogenous safeguards to prevent its malfunction.
The three human NOS have a 51–57% homology, and share a fundamental bi-domain
structure: an N-terminal oxygenase domain, with binding sites for zinc, iron proto-
phorphyrin IX (heme), L-arginine, (6R)-5,6,7,8-tetrahydrobiopterin (BH4), and a C-
terminal reductase domain, with binding sites for the two flavins, FAD, FMN, and for
NADPH. These two domains are linked by a calmodulin (CaM) recognition site
(Figure3). The crystal structures of the various NOS isoforms are gradually emerging
[152–157], and the truncated iNOS oxygenase domain, elongated in form, with an unusual
ab fold, has been memorably described as like a ‘baseball catcher’s mitt’, with the heme in
the palm of the mitt [152]. Structurally, however, the NOS oxygenase domain differs from
other heme oxygenases (cP450, peroxidase, catalase,) which have an a-helical distal pocket,
whereas the NOS distal pocket has a b-sheet structure [136].
All three NOS monomers form dimers in their catalytically active states. Once the dimers
are assembled, electrons donated by NADPH in the reductase domain are carried one by
one by FAD to FMN and on to the oxygenase domain, where they reduce the heme iron
and with BH4 supposedly catalyse oxidaton of L-arginine’s terminal, N-guanidino via the
intermediate, N
g-hydroxyl-l-arginine (NHA) to NO and citrulline [136,141,142]. This is a
two-step five-electron oxidation reaction. Ca
2+/CaM is required for electron flow from the
reductase to the oxygenase domains. However, whereas iNOS, which contains tightly
bound CaM, under normal basal physiological conditions, can produce NO at low ambient
Ca
2+ concentrations, and is thus largely Ca
2+ independent, nNOS and eNOS are totally
dependent on cellular Ca
2+ influx [136,141,142]. The amounts of NO produced by the
constitutive and inducible isoforms also vary dramatically. Ca
2+-dependent eNOS and
Figure 3. Human neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS)
domain structure. The PDZ domain is named after homologous domains in three proteins: PSD-95, DH/g, ZO-1.
Cobalamin in inflammation II 193nNOS produce NO continuously in short puffs and low amounts, with some modest up-
regulation in inflammatory immune response, and up-regulation or depression in
pathologies of unresolved inflammation, such as tumour growth or sepsis: Ca
2+-
independent iNOS, which is dependent for its expression on the transcription factors,
NFkB, STAT-1, AP-1 and IRF-1 [141,158], can yield a 700–1000-fold greater increase in
NO in a very short space of time.
We now come to another great point of controversy, which may be material to this
hypothesis: whether, in fact, NO is a direct product of the NOS [109], or whether it is
formed indirectly, after the formation of nitroxyl ion, NO
2, or other RNI species, or s-
nitrosothiols [141]. As with supposed iNOS over-activation and NO overproduction in
sepsis, NO production by NOS in general has been deduced from the generic breakdown
products, nitrite, nitrate, or effects on heme proteins such as soluble guanylate cyclase
induction, or oxidation of oxyhaemoglobin to methaemoglobin [141]. Studies using
specific NO electrodes or NO chemiluminescence assays have demonstrated that neither
nNOS nor iNOS, at least, can produce NO in the absence of SOD, which reduces NO
2 to
NO [109,159,160]. SOD also, of course, scavenges O2
2 produced by both FAD/FMN in
the reductase domain [161,162], and in the oxygenase domains of eNOS/nNOS in the
absence of BH4 [163,164]. Some evidence for NO
2 formation in BH4 depleted iNOS also
exists [165]. The general conclusion is that NOS may produce both NO and NO
2 in vivo,
in varying ratios, under different conditions [141]. The same is true of the NOS and O2
2
production, which may be contained or excessive. Depletion of L-arginine, for example,
increases NOS production of O2
2, and subsequent H2O2 [166–168]. In the latter case,
combinations of NO+O2
2,o rN O
2 and O2, result in excessive ONOO
2 and other RNIS
[136,169], redundant to the normal physiological needs for ONOO
2 and other RNIS for
signalling/cytocidal purposes and thus likely to result in pathology. Such varying NO/NO
2/
O2
2 ratios will be determined by the redox environment, and, perhaps more critically, the
availability of substrates and cofactors.
BH4: the Scarlet Pimpernel’s butterfly
The requirement for NOS enzyme activity of the cofactor BH4 (6R-5,6,7,8-tetrahydro-
biopterin) is absolute [170]. The absence of BH4 results in no NO production, even with
the L-arginine substrate [135]. Instead, BH4-free NOS catalyses a partially uncoupled
NADPH L-arginine oxidation reaction, resulting in excess O2
2 [164], and subsequent
excess H2O2, and ONOO
2.B H 4-free murine NOS, expressed in E. coli, yields citrulline
and N
d-cyanoornithine, nitrite and nitrate, but no NO [135]. (This is a good example of
how these much-relied on ‘NO’ markers, nitrite and nitrate, may mislead.) Moreover, BH4
depletion is associated with vascular pathology [171]. Endothelial dysfunction due to
eNOS inhibition, for example, has been reversed by BH4 administration to hypercholes-
terolaemic patients [172]. The addition of BH4 to eNOS increases NO production and
decreases O2
2 [173]. Furthermore, degrees of BH4 availability have been shown to limit
the onset of iNOS NO synthesis, in a dose-dependent manner [135]. Conversely, the
addition of exogenous BH4 to cells leads to earlier LPS-induced iNOS activity [170]. The
absence of BH4 also appears to inhibit cell growth and differentiation via the inhibitiono f
NOS activity [174].
BH4 (Figure4) is a pteridine, member of a class of pyrazino [2,3,d] pyrimidine
compounds, which include molybdopterin and folate. Pteridines were initially discovered
in the yellow pigments of the wings of butterflies by Sir Frederick Gowland Hopkins in
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giving rise to the name pteridine, from the Greek ‘ptera’ or wing. The isolation in 1957 of
the structure of fluorescent blue pigments in the eye of Drosophila melanogaster [176],
coincided with the discovery that the protozoan, Crithidia fasiculata required high doses of
folic acid for growth and that biopterin could substitute wholly for it. Thus, it began to be
appreciated that pteridines were not just pretty pigments, but had more complex biological
functions, from light-gathering molecules to enzyme cofactors in redox reactions and I-
carbon transfers [175]. Xanthine oxidase, for example, uses molybdopterin to catalyse the
last step in purine synthesis [177]. BH4 is an essential reducing cofactor of aromatic amino
acid hydroxylases (AAHs) in the metabolism of phenylalanine, tyrosine, tryptophan;
epinephrine; the monoaminergic neurotransmitters: dopamine, norepinephrine, serotonin,
and, en route to the latter, the sleep hormone, melatonin [177]. The observation of high
BH4 levels in tissues low in AAHs, blood, spleen, lungs, has led to other proposed roles: a
function of BH4 in haematopoietic cell proliferation and differentiation, based on the
specific appearance of BH4 during the differentiation of reticulocytes to erythrocytes, and
its cell cycle-dependent expression in various species, from mammalian thymocytes [178]
to the acellular slime mould Physarum, in which BH4 levels peak during S-phase, and
Drosophila embryos, which do not survive with BH4 mutation or inhibition [179]. The exact
role of BH4 in the NOS has proven to be somewhat elusive and mysterious. It had been
thought that it may have at least two functions: first, allosteric, stabilizing the NOS dimeric
structure and the high-spin heme iron conformation; as well as promoting L-arginine
substrate binding (which now appears not to be affected by BH4 [156]), second, a redox
role as a direct electron donor to the heme, promoting conversion of L-arginine to the
intermediate, NHA [153,156].
BH4, which is constitutive in liver, neuronal tissue and macrophages, can be additionally
induced by LPS, or cytokines, principally, interferon-c, TNFa and interleukin-1, in
macrophages, fibroblasts, endothelial and vascular smooth muscle cells [175]. De novo
BH4 synthesis requires the purine nucleotide, GTP, which is converted to BH4 in four
enzymatic steps, by three separate enzymes [175]. GTP cyclohydrolase (GTPCH), which
is rate limiting, catalyses the first step, yielding neopterin as a byproduct [175], a known
marker of immune activation [180]. GTP availability increases the GTPCH reaction
velocity in a concentration-dependent manner, and cytokine activation of cells significantly
increases levels of GTP. The mechanism of this inflammatory-induced up-regulation is
unknown [175].
Figure 4. Structure of 6R-5,6,7,8-tetrahydro-L-biopterin (BH4), the naturally occurring pterin cofactor of nitric
oxide synthases and amino acid hydroxylases. The standard nomenclature for numbering the positions of the
pteridine ring and the biopterin side chain is indicated.
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Now, remember what happens to Cbl in inflammation? When NFkB is activated, it cross-
talks to the transcription factor Sp1 [181], constitutively expressed in the eNOS promoter
and known to be essential for NO production [141], and also expressed in the iNOS
promoter region, along with the transcription factor IRF-1, essential for iNOS/eNOS
mRNA expression and NO production [151]. Sp1 up-regulates the production of TCII
[27], primed perhaps by interferons, particularly interferon-b, which simultaneously
increases TCIIr expression [65] through further cross-talk between IRF-1 and Sp1. So
more Cbl arrives intracellularly, where synthesis of GSCbl and its conversion to MeCbl and
AdoCbl is up-regulated by decreasing cellular pH [38,42]. MeCbl binds to MS, which is
then well armed to keep the folate pathway open and meet the increased needs in
inflammation for purine nucleotide synthesis, essential for RNA synthesis and DNA
replication. AdoCbl binds to MCoAM, and, as the cell’s energy needs increase, AdoCbl,
via MCoAM’s impact on the TCA cycle and oxidative phosphorylation, ensures a steady
stream of ATP, and the reducing equivalents, NADH+H
+ and FADH2, for maximal
efficiency of key defence enzymes. Each turn of the TCA cycle produces 1mol GTP, and
coupled to oxidative phosphorylation, 10mol ATP [51]. ATP may be converted to GTP,
and vice versa, but the ATP/GTP ratio in cells is relatively constant, with total cell
concentrations of adenine nucleotides, ATP+ADP+AMP, being four to six times greater
than those of guanine nucleotides, GTP+GDP+GMP. ATP and GTP are derived from
AMP and GMP via the common ribonucleotide precursor in the de novo purine nucleotide
synthesis pathway, inosine 5
1-monophosphate (IMP), an energy expensive pathway in
terms of ATP consumed per mole of IMP produced. The conversion of IMP to AMP and
GMP is tightly and mutually regulated: with IMP to GMP requiring ATP, and IMPt o
AMP requiring GTP, as energy sources. So when there is sufficient ATP in the cell, GMP
is synthesized from IMP, and when sufficient GTP exists, AMP is synthesized from IMP
[177]. Thus, degrees of Cbl deficiency may ultimately impact on both levels of ATP and
GTP, and increasingly depressed production of GTP will ultimately impact on BH4 status
– IMP dehydrogenase inhibitors reduce BH4 synthesis [175]. Finally, in turn, this will
inhibit iNOS NO production. A deficiency of BH4 will also ultimately affect its catalytic
recycling by AAHs, resulting in decreased catecholamine and monoaminergic neuro-
transmitter synthesis [113]. Perhaps then the characteristic unresponsive hypotension of
sepsis and septic or traumatic shock may be just as attributable to an increasing decline in
catecholamine synthesis, as to the supposed overproduction of NO. Such LPS-induced
hypotension has been shown to precede iNOS activation in rodents [182]. Furthermore,
there may be an increase in oxidized and therefore ineffectual catecholamines such as
adrenochrome [183] and adrenolutin, which also disturb mental equilibrium [184]. As Cbl
is also critical to the synthesis of acetylcholine and the importance of the CNS and neuro-
immune cholinergic pathway in inflammation has been well demonstrated [95,185], the
characteristic mental obfuscation and loss of consciousness in sepsis [186] may also be as
much consequences of depressed GTP synthesis as of supposed NO overproduction. Such
a Cbl/GTP deficiency would result in a decrease in acetylcholine and other neurotrans-
mitters, an increase in toxic catecholamine metabolites, and unregulated cytokine
production. Indeed, given the low–high and vice versa NO/TNFa regulatory correlation
discussed earlier, together with established high levels of TNFa in sepsis [187], and
observed 83% increase in spinal fluid TNFa levels in Cbl deficiency [188], the argument
for NO overproduction in sepsis looks tenuous, whereas it has been shown that higher
levels of ATP in septic patients have a positive significant correlation with survival [189].
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and consequently BH4 and consequently a decline in production of NO from iNOS, which
would argue further against the popular view of increasing NO production in sepsis and
other pathologies of unresolved inflammation.
Cbl, aKG and arginine: close collaborators and distant allies
The production of succinyl CoA in the TCA cycle is not, of course, solely dependent on
Cbl. a-Ketoglutarate, aKG, an important intermediate in the cycle, derived from citrate, is
equally critical to succinyl CoA formation and the onward role of the cycle [51]. aKG is a
form of ornithine, and its production is important not just for the activity of the TCA cycle,
but for that of the urea cycle, the major mechanism for the removal of ammonia (NH4)
produced by protein catabolism [113]. When aKG leaves the TCA cycle it is transaminated
with glutamine to form glutamate, which can exit mitochondria and be further converted to
other non-essential amino acids. In the CNS, aKG is converted to the neurotransmitters,
glutamate and GABA, c-aminobutyric acid. Glutamate can also be produced from aKG in
mitochondria by the mitochondrial enzyme glutamate dehydrogenase in the presence of
NADH or NADPH and ammonia [113]. The amino group thus incorporated into
glutamine is used by aminotranferases to form other amino acids. Glutamate is a precursor
of ornithine, in turn a precursor of arginine. In the urea cycle, which depends on a supply of
glutamate, via aKG from the TCA cycle, ornithine and arginine are continuously
interconverted, and the arginine formed there is not available for protein synthesis and
NOS NO synthesis [113]. The synthesis of arginine for the latter begins in the intestinal
mucosa, which is rich in glutamine and enzymes that convert glutamate via ornithine to
citrulline. The final conversion of citrulline to arginine occurs in the renal proximal tubular
cells, which lack the arginase of the urea cycle, and are responsible for 60% of net arginine
synthesis [190]. Since citrulline is also a by-product of NO formation, most cells have the
capacity to synthesize arginine to some degree, so that there is also in effect a citrulline–
NO–arginine cycle, analogous to the recycling of arginine in the urea cycle [190]. Yet this
recycling provides only about 50% of the L-arginine cofactor required by NOS to produce
NO. The other 50% is supplied by arginine production from protein catabolism and
synthesis [190]. Although no studies evaluate the role of the latter in regulating arginine
availability for iNOS NO synthesis in different cell types, it is probably an important factor,
as it is in arginine homeostasis, a balance kept by dietary arginine, endogenous arginine
production and degradation [190]. In sepsis, where there is supposed iNOS NO
overproduction, plasma arginine falls by as much as 50–60%, and the reason for this is
not understood. Although high levels of iNOS/NO can inhibit protein synthesis, and
inflammation induces both arginases and plasma arginine transporter up-regulation [190],
thus potentially increasing plasma arginine clearance, there may be a different explanation,
consistent with the hypothesis that in pathologies of unresolved inflammation, not enough
NO is produced from NOS, but instead excess RNIS and ROS, so that the redox balance is
lost, leading to increasing bioenergetic failure. High metabolic rates and increased
catabolism without corresponding anabolism, characteristic of sepsis, mean that the liver
and kidneys have to deal with the clearance of increasing levels of ammonia, the final
breakdown product of protein catabolism. Glutamine, which constitutes 50% of circulating
amino acids, and serves as an ammonia transporter, is diverted, as a result of lactic acidosis,
from the intestinal mucosa to the kidneys – breakdown of the intestinal mucosa integrity is
an early symptom of sepsis [191]. The uptake of glutamine by the liver, needed for the urea
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for the formation of urea [113]. If the redox balance is not regained, persistent lactic
acidosis and protein catabolism mean that the already dysregulated liver and kidneys start
to fail. High ammonia concentrations lead to increasing liver sequestration of aKG as
glutamate from the TCA cycle. This in turn reduces further the already reduced synthesis
of ATP, leading to coma and death.
Thus, it is possible to see why there are two sources of succinyl CoA in the TCA cycle:
Cbl functions as the back-up disc for aKG. If Cbl status is replete, fluctuations in aKG will
be minimized, homeostasis of the TCA cycle ensured, in turn ensuring homeostasis of the
urea cycle, and the availability of arginine outside the urea cycle for protein synthesis and
NOS NO production. This is why the 5g supra-physiological doses of Cbl used for 40 years
by the French as an antidote to cyanide poisoning work so dramatically, restoring
metabolism in hours and reversing damage to vital organs, so that liver function is normal
at discharge, just 2 days after fatal doses of cyanide [66,72–76]. Cbl does this not just by
binding to CN, but by performing all its normal metabolic tasks, which include the supply
of all the NOS substrates and cofactors: the purine nucleotides, FAD and FMN, via MS;
BH4 via GTP; arginine by supporting aKG and keeping the onward momentum of the
TCA cycle rolling (consequently decreasing glycolysis and reversing lactic acidosis);
NADPH, as we will see, via Cbl’s impact on G6PDH and the pentose phosphate pathway;
and last but not least, even heme synthesis, the organic portion of which requires eight
residues each of glycine and succinyl CoA [192]. Cbl’s critical role in heme synthesis
particularly demonstrates the pivotal role Cbl may play in inflammation control, not only
because many heme proteins such as cP450, catalase, HO-1, have anti-inflammatory
functions, but because inducible HO-1 promoted by Cbl (USP 5,674,505), continually
breaks down heme, via biliverdin, to the potent antioxidant, bilirubin. However, the
simultaneous up-regulation of the TCs in inflammation ensures both the rapid regeneration
of heme, and thus of key heme proteins, and a consequent increased potential production
of bilirubin, as needed. (That AdoCbl via MCoAM is rate regulating in particular for the
synthesis of the heme of haemoglobin has been specifically observed with heme staining of
transparent 2 day old zebrafish larvae using o-dianisidine. T. Penberthy, pers. commun.)
eNOS is depressed in sepsis [107,193] and other pathologies of unresolved inflamma-
tion, and the evidence for alleged iNOS overexpression under these conditions is largely
indirect or equivocal. iNOS may in fact be depressed as well as malfunctioning. Moreover,
murine iNOS knockout models show that suppression of iNOS offers no protection against
organ damage and mortality from LPS. iNOS expression and NO production are also
dependent on the expression of interferons and the transcription factor, IRF-1, in the iNOS
promoter. Might this be because interferons up-regulate TCS and their receptors,
increasing and sustaining the arrival of more Cbl intracellularly, so that subsequently these
increased local levels of Cbl, as AdoCbl and MeCbl, can ensure the assembly of all
substrates and cofactors to enhance NO production, not only via iNOS, but eNOS, as seen
in recent studies? [17].
NO: friend or foe?
If it were not for the fact that it is a colourless compound, NO itself might well deserve the
soubriquet‘ScarletPimpernel’. Unknown until the last 25or so years, the smallest but potent
workingmammalian molecule, NO, a paramagnetic gas, is produced enzymatically in diverse
locations throughout the body and being both lipophilic and hydrophilic is easily diffusible
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[64]. For example, in the ryanodine receptor/Ca
2+ release channel (RyR), NO nitrosylates
only one out of 50 free cysteines per RyR, to alter the Ca
2+ CaM/RyR interaction, sensitizing
the channel to positive or negative Ca
2+ regulation [194]. This extraordinary precision can
only happen at a restricted O2 concentration. NO, a second messenger for post-translational
modification, is responsible for a wide diversity of critical functions: immune regulation and
anti-microbial defence; neurotransmission and cerebral blood flow; smooth muscle
relaxation; platelet aggregation or inhibition; exchange of gases in tissues; bronchodilation;
glomerular filtration; gut peristalsis; penile erection; cardiac contractility; modulation of
ligand-gated receptors (N-methyl-D-aspartate receptor) the Ca
2+-dependent potassium
channel, the cardiac Ca
2+ release channel, cyclic nucleotide cation gated channels, Janus
kinases, tyrosine phosphatases; peptide hormone release, and more [86,195–197].
To effect all of these physiological processes, NO assumes three redox forms, the free
radical NO
N itself, nitrosonium (NO
+) and the nitroxyl anion (NO
2). So the term NO is a
collective description. These varying redox forms of NO have particular affinities for
particular biological targets: NO
N reacts with oxygen, superoxide O2
2 and redox metals;
NO
2 with SH groups and metals; NO+ undergoes addition and substitution reactions with
nucleophiles in aromatic compounds and electron-rich bases [64]. Fluctuations between
these redox forms and their target products are of central importance to physiological
homeostasis. Principally NO’s strong affinity for transition metals results in its combination
with the target heme iron, to form very stable catalytic Fe
2+–NO iron–nitrosyl complexes,
and/or combine with critical thiol residues, to form s-nitrosothiols, or s-nitrosylate proteins
[64,86,138]. Such combinations can simultaneously activate some enzymes and deactivate
others, modifying protein function or initiating gene expression. Both Cox I and II
[138,198] and soluble guanylate cyclase and thence the second messenger cGMP
[199,200] are activated by NO binding to their Fe
3+, whereas cytochrome c oxidase,
complex IV of the oxidative phosphorylation, electron transport chain, is deactivated by
NO/Fe
3+ binding [201] as are cP450 enzymes [202], indoleamine 2, 3-dioxygenase (IDO)
[203], important in bacteriostasis, and, indeed, NOS itself [19–21]. Enzymes with catalytic
thiols deactivated by s-nitrosylation include glyceraldehyde phosphate dehydrogenase,
inhibited by NO-promoted ADP-ribosylation [204,205], protein kinase C [206], c-
glutamylcysteinyl synthetase [207], alcohol and aldehyde dehydrogenase [208], aldolase
[208], cathepsin B [208], O
6-methylguanine-DNA-methyltransferase [208], neutrophil
NADPH oxidase [86,138] and at least seven members of the caspase family, involved in
apoptotic signal transduction and cytokine maturation [86,209] and one of the most
important antioxidant enzymes, GPX [210]. Conversely, s-nitrosylation of tissue
plasminogen activator activates its vasodilatory and anti-platelet effects [211].
When the redox balance is maintained and oxidative stress is not extreme or persistent,
such NO-derived enzymatic activation and deactivation will occur reversibly, in a
complementary manner, both simultaneously and/or in a relay system, preventing NO
toxicity. But persistent or extreme oxidative stress may render NO toxic by shifting the
balance between NO redox species and their target reactants and end products, from high
output of s-nitrosothiols, resistant to O2 and O2
2 interaction, the principal form in which
NO is neutralized for safe transport to tissues [64] via haemoglobin, myoglobin, albumin
[212] and GSH [213–215], to increased production of RNIS such as the reactive
intermediate, ONOO
2, via increased reactions with H2O2 and O2
2, and other ROS, which
can prolong oxidative stress indefinitely, leading to increasing enzymatic malfunction,
which will, of course, include malfunction of all three NOS.
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produces less NO and more O2
2, then because the relative fluxes of NO and O2
2 modulate
the oxidation of critical enzymatic and other protein thiols by ONOO
2 and other RNIS,
and because ONOO
2 and O2
2, rather than NO, inactivate aconitase [216] in the TCA
cycle, and also inactivate NADH dehydrogenase and succinate dehydrogenase, complexes
I, II and III of the oxidative phosphorylation, electron transport chain [217], as well as
deregulating poly-ADP-ribosyl transferase [204,205], the stage is thus set for terminal cell
function dysregulation and energetic failure. Of course, normally this does not happen due
to powerful antioxidant defence systems, which are well primed and in place before the
conveniently delayed induction of NO by iNOS peaking at 6hours. But sometimes these
systems fail, and when they do, this hypothesis posits, it is because they have lost their
‘back-up disc’, as a result of insufficient, or non-functional, Cbl status. Moreover, it seems
that there is a fine hierarchical balance relationship between key anti-oxidant enzymes,
which can be equally detrimental if disturbed, even though some of the enzymes may
remain functional. With certain anti-oxidant enzymes more is not necessarily better.
Indeed, it may be worse: five- and 10-fold increases in Mn-SOD and Fe-SOD, respectively,
sensitize E. coli to paraquat toxicity [218,219]; Cu/Zn-SOD transfectants of mouse
epidermal cells JB6 possess increased sensitivity to DNA strand breakage and growth
inhibition in the presence of O2
2 and H2O2 from xanthine/xanthine oxidase [220], whereas
a concomitant increase in catalase in a double transfectant can correct this [220]. Similarly,
in protection from ischaemia-reperfusion injury, a combination of Cu/Zn-SOD and
catalase worked better than either alone [221]. Again, it has been observed in several
systems that an increase in Cu/Zn-SOD is accompanied by an increase in GPX [222], with
a high ratio of activity of GPX over Cu/Zn-SOD related to notably increased growth
potential and resistance to killing by paraquat in NIH-3T3 transfectants [223]. Catalase
scavenges H2O2 produced by Cu/Zn-SOD catalysis, but GPX, the primary H2O2
scavenger, additionally can destroy hydroperoxides, which catalase cannot, so the activity
status of GPX is crucial and superior in the hierarchy, and ultimately that is dependent on
the status of GSH, which apparently depends on the activity of GSH reductase, as well as
the availability of cysteine, derived from serine, which provides the carbon skeleton, with
supply of the sulphur dependent in turn on the reduction of homocysteine by MeCbl.
GSH, Cbl and NO: an eternal triangle?
GSH, C10H17N3O6S, is actually a tripeptide, c-glutamylcysteinylglycine, and so it has a less
obvious debt to AdoCbl, via AdoCbl support of aKG in the TCA cycle, which ensures a
supply of glutamate. An additional debt to MeCbl is in the supply of glycine, formed from
the breakdown of serine in a reaction requiring pyridoxal phosphate and THF [113], the
latter dependent on Cbl status for its availability [224]. As ubiquitous as Cbl and NO, GSH
is a major reductant and detoxifier, involved in drug conjugation, and is a cofactor
modulating O2
2 production in many key enzyme systems, including glycolytic enzymes
[91,214,225–227]. This function of GSH is of particular importance in the NOS. GSH is
essential for leukotriene synthesis [113], amino acid transport [113], maintenance of
erythrocyte membrane integrity [113], and reduction of peroxides formed during oxygen
transport [91]. GSH is the principal thiol involved in the correct formation and degradation
of protein disulphide bridges and through thiol–disulphide exchanges ensures proteins are
folded into their native conformation [228]. Lysozyme, ribonuclease, albumin and insulin
are notable examples of important proteins requiring GSH for formation [228]. GSH also
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[228]. The functionally correct ratio of S-H groups to S-S is ensured by very high levels of
GSH in cells, of up to 10mM. In erythrocytes, for example, this results in a 100:1 ratio of
GSH to GSSG [91]. Thus, the maintenance of very high levels of GSH, important in every
respect, is critical for good immune function and the resolution of inflammation. GSH and
GPX rapid depletion in sepsis has already been noted, a depletion that affects both arms of
the immune system, with decreased lymphocyte response to mitogens in the relative
absence of GSH [229]. Given the shift in redox balance entailed by the inflammatory
immune response, the recycling of GSH by GSH reductase is liable to be ultimately
inadequate without de novo GSH synthesis, and, as seen in pathologies of unresolvable
inflammation, even this can fail. The GSH-sparing/promotional role of Cbl in preventing
this appears to have been completely overlooked [1].
Yet, over 50 years ago it was observed that in pernicious anaemia/Cbl deficiency, in both
rats and humans, levels of GSH in blood are very considerably depressed, and that these
low levels return to normal promptly, and without exogenous GSH or GSH precursor
administration, simply by treating the Cbl deficiency. Moreover, an initial overshoot of
GSH was observed on correction of the Cbl deficiency [230,231]. That this is peculiar to
Cbl was proved by studies showing that the normal reduction of S-S groups remains
unaffected in iron or folic acid deficiency [231]. Contemporaneously, it was also shown
that a combination of GSH and Cbl was synergistically more powerful than either alone in
the reactivation of a range of enzymes with active S-H groups in the E. coli mutant 113-3
[232]. It was noted, however, that certain other enzymes were conversely deactivated by
GSH alone [232]. These studies were, of course, performed in the era before the discovery
of NO’s biochemical role. With hindsight, given the NO-analogous effect of Cbl and GSH
on enzyme activation/deactivation, one can see that these GSH/Cbl effects, mediated
perhaps by possible Cbl oxidation and reduction of thiols [232–236], are part of bacterial
defence against NO generated by macrophages in the phagocytic burst. In fact, as the
studies used a combination of 50mM GSH to 50 mg Cbl, it is likely perhaps that GSCbl
was formed in the cultures. A noteworthy observation of these studies was that the GSH/
Cbl combination was most effective at regenerating activity in aged enzymes [232], thus
simulating the effects of possible GSCbl on enzymes during oxidative stress, characteristic
of inflammation, and again, with hindsight, perhaps indicating the potential importance of
the controlled but increased rate of GSCbl formation in inflammation. Pertinently,
enzymatic activity of G6PDH with added substrate was assayed in a range of pH, at 37uC,
with Cbl and GSH, and found to be least active at pH8.5, and most active at pH6.5 – this
is interestingly coincident with the pH variable for GSCbl’s rate constant in inflammation.
Most crucially from this viewpoint, the combination of GSH/Cbl was able to restore the
activity of both lactate dehydrogenase and G6PDH [232], key enzymes in the pentose
phosphate pathway, the latter responsible, with glycolysis and the TCA cycle, for the
synthesis of the reducing equivalent, NADPH [94]. The activity of G6PDH is essential for
the maintenance of erythocyte GSH in its reduced state via the formation of NADPH [94]
and, of course, NADPH is essential to the function of key enzyme systems from cP450 to
GSH reductase, GPX and the NOS. An irreversible decline in NADPH production during
inflammation will have serious consequences, and will certainly result in increasingly less
coupled NOS reactions and less NO. Other enzymes activated by Cbl/GSH include:
pyruvic transaminase, stearic acid oxidase, glycine and alamine deaminase, cysteine
desulphurase, serine dehydrase, maltase, lactase, lysine and ornithine and glutamic
decarboxylase. [232] This last is of obvious significance for supply of aKG, arginine,
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this Cbl+GSH enzymatic activation was a general effect, not restricted to a particular class.
These early studies all provide forgotten evidence for an intimate co-dependent
relationship between GSH and Cbl. The nexus of this co-dependence is in what has
been described as a SAM ‘switch’ for the two alternating fates of homocysteine [127]
(Figure2). Homocysteine in the MeCbl MS-dependent methionine cycle is used to
regenerate methionine, which reacts with ATP – from the AdoCbl MCoAM supported
TCA cycle – to yield SAM, the universal methyl donor. If there is an excess of methionine,
some of it will be converted to ammonia and a-ketobutyrate, which is decarboxylated to
yield propionyl CoA [113] then converted to succinyl CoA and thence re-enters the TCA
energy generation cycle. Some excess methionine will also be utilized in gluconeogenesis
[113]. This shuttling of excess methionine back to the TCA cycle to repay the ATP debt for
SAM shows the complementary, co-operative functions of the two Cbl coenzymes,
everywhere apparent given the universal roles of MeCbl/AdoCbl, respectively, promoted by
SAM and ATP. Levels of SAM are hence ultimately determined by Cbl status in general, as
much as by dietary intake of methionine. If Cbl status is good, ATP and SAM will be
abundant. High levels of SAM activate the SAM ‘switch’ that links Cbl to the synthesis of
GSH, as SAM inhibits the provision of methyl folate for MS reduction of homocysteine to
methionine, and increases cystathionine b-synthase, which transulphurates homocysteine
to cystathionine, a precursor of cysteine and thence GSH [127].
This ultimate dependence of GSH status on Cbl status will have a direct impact on NO
regulation because cellular thiol status has a major impact on NO species formation. The
induction of iNOS is thus linked to the induction of GSH synthesis [237]. In the presence
of thiol, s-nitrosation is preferential to O- or N-nitrosation [238], and, in health and a
healthy immune response, s-nitrosothiols predominate over other nitrosated forms.
Moreover, GSH and other thiols limit NO/O2
2 interactions that produce excessive
RNIS and ROS resulting in lipid peroxidation, excess S-H oxidation and other detrimental
consequences [64,84,85,240]. For example, ONOO
2 formed by NO/O2
2 interaction can
react with GSH to give s-nitroglutathione (GSNO2), which decomposes spontaneously to
NO [241]. So the normal Cbl-GSH-dependent preponderance of RS-NOs over RNIS
favours the positive aspects of NO regulation over the pathologies of NO dysregulation.
The brilliantly host advantageous deployment in the Cbl–GSH–NO relationship of the
potentially dangerous dual aspects of NO can be well illustrated by what happens in
bacteriostasis/phagocytosis. Many bacteria contain similar defence systems to eukaryotes
[86], such as SOD, GSH [242]/GPX and Cbl, in addition to an NO reductase, and
G6PDH. During bacteriostasis and phagocytosis, however, neutrophils secrete large
quantities of TCI, along with myeloperoxidase in the secondary granules. These TCIs act
as magnets that leach Cbl from bacteria [243] (analogously to lactoferrin and iron), which
means that bacteria are effectively disarmed, bereft of the back-up system that sustains their
G6PDH and other enzymatic activity, in particular, their GSH/GPX, which is rapidly
consumed in the increased acidity of the phagocytic burst and exposure to high levels of
NO/ONOO
2/O2
2/H2O2 from the host. This lethal assault also affects the host’s defences,
with a 25% utilization of GSH in the first 10min of phagocytosis [82]. However, the host is
well armed to regenerate and synthesize GSH de novo, with significant amounts of AdoCbl
on TCIs, in situ, not to mention incoming extra supplies from the phagocytosed pathogen.
It has also been noted that s-nitrosothiols, such as GSNO, or s-nitrosocysteine, have a
significantly more potent virustatic, parasiticidal, and bactericidal activity than NO itself,
with trans-s-nitrosation implicated [81]. The regeneration of GSH, ultimately dependent
202 C. Wheatleyon Cbl, is critical in this respect. One way or another it seems, the effects of NO cannot be
subtracted from the effects of GSH and Cbl and when they are in balance, when Cbl status
is sufficient, NO, GSH and Cbl may continuously regulate the NOS.
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